BRIEF-Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

TPST

0.00

July 21 (Reuters) - Tempest Therapeutics Inc TPST.O:

  • TEMPEST ANNOUNCES DEVELOPMENT COLLABORATION WITH SENLANG BIOTECHNOLOGY FOR TPST-4003, A CD7-TARGETED NEXT-GENERATION IN VIVO CAR-T

  • TEMPEST THERAPEUTICS - FIRST PATIENT DOSING FOR TPST-4003 TRIAL EXPECTED IN Q4 2026

  • TEMPEST THERAPEUTICS - CO AND SENLANG TO DEVELOP TPST-4003 WITH TRIAL IN CHINA FOR MG AND MS

Source text: ID:nGNX9T07mm

Further company coverage: TPST.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.